Breaking News

NovaQuest Invests in Bend Bioscience to Broaden CoreRx Offering

Bend Bioscience to focus on new innovation, product development, and manufacturing.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bend Bioscience and QHP Capital, the management company for NovaQuest Private Equity, plan to invest in a new operation in Bend, OR, an emerging biotechnology R&D and manufacturing hub.  The Bend Bioscience team, as part of CoreRx, will focus on drug delivery R&D partnerships, product development, and early phase manufacturing for enhanced formulations utilizing particle engineering-based drug delivery technologies.    “This is an exciting development,” said Ajay Damani, CE...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters